Skip to main content
IMMUPHARMA PLC logo

IMMUPHARMA PLC — Investor Relations & Filings

Ticker · IMM ISIN · GB0033711010 LEI · 213800VZKGHXC7VUS895 IL Professional, scientific and technical activities
Open in API
Filings indexed 471 across all filing types
Latest filing 2026-05-05 Capital/Financing Update
Country GB United Kingdom
Listing IL IMM

About IMMUPHARMA PLC

https://www.immupharma.co.uk/

ImmuPharma PLC is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The company's primary focus is on creating novel treatments for serious medical conditions with significant unmet needs. Its core activities involve advancing a pipeline of drug candidates through research and various stages of clinical development, leveraging its expertise in peptide technology.

Recent filings

Filing Released Lang Actions
IMM initiatesIND-Enabling Program for Kapiglucagon
Capital/Financing Update Classification · 95% confidence The document is an announcement from ImmuPharma PLC about initiating IND-enabling activities for a drug development program (Kapiglucagon). It discusses regulatory strategy, pre-IND meetings with the FDA, and development plans. There are no financial statements, quarterly or annual results, or detailed financial data. The document is a corporate update on a development program and regulatory progress, typical of a capital/financing or corporate update. It is not an earnings release, annual report, or regulatory filing of financial data. It is also not a report publication announcement or certification. The content fits best under Capital/Financing Update (CAP) as it relates to development progress and regulatory strategy impacting the company's capital and development pipeline.
2026-05-05 English
Holding(s) in Company
Major Shareholding Notification Classification · 98% confidence The document is a UK RNS TR-1 notification of major holdings (notification of crossing a voting rights threshold), detailing shareholding percentages, dates, ISIN, and notification obligations. This matches the Major Shareholding Notification category.
2026-04-10 English
Chairman’s Open Letter to Shareholders
Declaration of Voting Results & Voting Rights Announcements Classification · 78% confidence The document is an RNS Reach announcement titled “Chairman’s Open Letter to Shareholders,” issued after a General Meeting held on 7 April 2026. It prominently reports that both resolutions were approved by shareholders, including the exact vote percentages (91.46% and 88.91%), which is characteristic of a Declaration of Voting Results filing. Although it also discusses the use of proceeds from the approved fundraising, the primary regulatory function is to communicate the formal voting outcomes. Therefore, it best fits the Declaration of Voting Results & Voting Rights category (Code: DVA).
2026-04-09 English
P140 Program Update
Regulatory Filings Classification · 85% confidence The document is an RNS announcement by ImmuPharma PLC providing a corporate update on its P140 program (patent progress, supporting data, partnering discussions). It is not an earnings release, financial report, AGM materials, dividend notice, or any of the specialized categories. It is a general regulatory news announcement that does not fit other specific types and thus falls under the fallback category “Regulatory Filings (RNS).”
2026-03-27 English
Result of WRAP Retail Offer and TVR
Capital/Financing Update Classification · 90% confidence The document is an RNS announcement by ImmuPharma PLC detailing the outcome of its WRAP Retail Offer and associated fundraising (gross proceeds, subscription shares, retail offer shares, Value Payment Shares, Fee Shares), and providing an update on capital raised and planned share allotment. This is a direct update on the company's financing activities and changes to its capital structure, not a full financial report or a simple publication notice. Therefore, it best fits the “Capital/Financing Update” category.
2026-03-23 English
Publication of Circular
Report Publication Announcement Classification · 95% confidence The document is a short announcement (under 5,000 characters) from ImmuPharma PLC regarding the publication and distribution of a circular for an upcoming General Meeting. It explicitly states that the circular has been sent to shareholders and will be available on the company website. Following the 'Menu vs Meal' rule, this is an announcement of a report/document rather than the document itself, making it a Report Publication Announcement (RPA).
2026-03-19 English

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.